Treatment of acromegaly with SS analogues: Should GH and IGF-I target levels be lowered to assert a tight control of the disease?

Journal of Endocrinological Investigation

Volumn 27, Issue 11, 2004, Pages 1040-1047

  Cozzi, R ^a   Attanasio, R ^a   Grottoli, S ^b   Pagani, G ^c   Loli, P ^a   Gasco, V ^b   Pedroncelli, A M ^d   Montini, M ^c   Ghigo, E ^b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d Novartis Pharma   (Italy)

Author keywords

Acromegaly; Gender; GH; IGF I; Lanreotide; Medical treatment; Normal values; Octreotide; SS analogues

Indexed keywords

BIOLOGICAL MARKER; DRUG DERIVATIVE; HUMAN GROWTH HORMONE; SOMATOMEDIN C; SOMATOSTATIN;

ACROMEGALY; ADULT; AGED; ARTICLE; BIOASSAY; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; POSTMENOPAUSE; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; ENDPOINT DETERMINATION; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POSTMENOPAUSE; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEX FACTORS; SOMATOSTATIN;

EID: 15744377370     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03345307     Document Type: Article

References (42)

1. Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet 1998, 352: 1455-61.
2. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970, 39: 1-16.
3. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998, 83: 2646-52.
4. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, et al. Guidelines for Acromegaly Management. J Clin Endocrinol Metab 2002, 87: 4054-8.
5. Heron I, Thomas F, Dero M, Poutrain JR, Henane S, Catus F, et al. Treatment of acromegaly with sustained-release lanreotide, a new somatostatin analog. Presse Med 1993, 22: 526-31.
6. Giusti M, Gussoni G, Cuttica CM, Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. J Clin Endocrinol Metab 1996, 81: 2089-97.
7. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997, 82: 18-22.
8. Attanasio R, Barausse M, Cozzi R. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest 2001, 24: 209-16.
9. Cozzi R, Barausse M, Sberna M, Lodrini A, Franzini A, Lasio G, et al. Lanreotide 60 mg, a longer acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. Pituitary 2000, 3: 231-8.
10. Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 2003, 88: 5258-65.
11. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002, 87: 99-104.
12. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995, 80: 3267-72.
13. Flogstad AK, Halse J, Bakke S, Lancranjan J, Marbach P, Bruns Ch, et al. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab 1997, 82: 23-31.
14. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, et al. Four-year treatment with octreotide-LAR in 110 acromegalic patients: the predictive value of short-term results. J Clin Endocrinol Metab 2003, 88: 3090-8.
15. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002, 87: 3013-8.
16. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
17. Swearingen B, Barker 2nd FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83: 3419-26.
18. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993, 86: 293-9.
19. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994, 41: 95-102.
20. Parkinson C, Ryder WDJ, Trainer PJ, and the Sensus Acromegaly Study Group. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 2001, 86: 5240-4.
21. Engström BE, Burman P, Karlsson FA. Men with acromegaly need higher doses of octreotide than women. Clin Endocrinol (Oxf) 2002, 56: 73-7.
22. Cozzi R, Barausse M, Lodrini S, Lasio G, Attanasio R. Estroprogestinic pill normalizes IGF-I levels in acromegalic women. J Endocrinol Invest 2003, 26: 347-52.
23. Attanasio R, Barausse M, Cozzi R. Raloxifene lowers IGF-I levels in acromegalic women. Eur J Endocrinol 2003, 148: 443-8.
24. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83: 2730-4.
25. Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW. Long-term treatment outcome in acromegaly. GH & IGF-I Res 2003, 13: 185-92.
26. Ajuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 1613-7.
27. Shalet SM. Biochemical monitoring of disease activity after surgery for acromegaly. J Clin Endocrinol Metab 2004, 89: 492-4.
28. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001, 22: 53-74.
29. Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. GH & IGF-I Res 2003, 13: 171-84.
30. Chapman IM, Harman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower post-glucose nadir GH concentrations in men than in women. J Clin Endocrinol Metab 1994, 78: 1312-9.
31. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002, 87: 3537-42.
32. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004, 89: 495-500.
33. Shibasaki T, Masuda A, Hotta M, Yamauchi N, Hizuka N, Takano K, et al. Effects of ingestion of glucose on GH and TSH secretion: evidence for stimulation of somatostatin release from the hypothalamus by acute hyperglycemia in normal man and its impairment in acromegalic patients. Life Sci 1989, 44: 431-8.
34. Brabant G, von zur Mühlen A, Wüster C, Ranke MB, Kratzsch J, Kiess W, et al. Serum Insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Hormone Res 2003, 60: 53-60.
35. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89: 667-74.
36. Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 658-61.
37. Mukherjee A, Monson JP, Jönsson PJ, Trainer PJ, ShaletSM, on behalf of the KIMS International Board. Seeking the optimal target range for Insulin-Like Growth Factor I during the treatment of adult Growth Hormone disorders. J Clin Endocrinol Metab 2003, 88, 5865-70.
38. Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM, Trainer PJ. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clin Endocrinol (Oxf) 2002, 57: 59-64.
39. Colao A, Amato G, Pedroncelli AM, Baldelli R, Grottoli S, Gasco V, et al. Gender and age-related differences in the endocrine parameters of acromegaly. J Endocrinol Invest 2002, 25: 532-8.
40. Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Kjellberg RN, Van Wyk JJ. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Amer J Med 1980, 69: 571-5.
41. Yakar S, Wu Y, Setser J, Rosen CJ. The role of circulating IGFI. Endocrine 2002, 19: 239-48.
42. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004, 89: 2789-96.